Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Employees

122

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/11/26	HK$2.670	-5.65%	1,050,000
02/11/26	HK$2.830	+1.43%	221,000
30/10/26	HK$2.790	-1.24%	392,000
29/10/26	HK$2.825	-0.53%	282,000
28/10/26	HK$2.840	+2.34%	1,049,500

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.399CNY

Average target price

4.150CNY

Spread / Average Target

+73.00%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Antengene Corporation Limited

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Antengene Corporation Limited

Company calendar

Market Closed - Hong Kong S.E. 12:08:08 03/11/2026 +04			5-day change	1st Jan Change
2.670 ^HKD	-5.65%		-3.78%	-29.55%

10-26	Antengene Corporation Limited Presents Latest Clinical Results For ATG-022 And ATG-037 At ESMO 2026	CI
10-09	Antengene Corporation Limited Announces Presentation Of Latest Preclinical Results Of ATG-207 At ACR 2026	CI

Market Cap	1.65B 1.95B 248M 221M 203M 185M 346M 23.48B 353M 2.43B 978M 12.39B 931M 911M 39.14B	P/E 2026 *	4.53x	P/E 2027 *	-18.5x
Enterprise Value	1.65B 1.95B 248M 221M 203M 185M 346M 23.48B 353M 2.43B 978M 12.39B 931M 911M 39.14B	EV / Sales 2026 *	1.99x	EV / Sales 2027 *	4.88x
Free-Float	62.79%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	6996	Delayed
Tradegate	722	Real-time
Börse Stuttgart	722	Delayed
Deutsche Boerse AG	722	Delayed

10-26	Antengene Corporation Limited Presents Latest Clinical Results For ATG-022 And ATG-037 At ESMO 2026	CI
10-09	Antengene Corporation Limited Announces Presentation Of Latest Preclinical Results Of ATG-207 At ACR 2026	CI
09-21	Antengene Corporation Limited Doses First Patient in Pivotal Phase III CLINCH-3 Study of ATG-022	CI
08-25	Antengene Corporation Limited Receives HREC Approval In Australia For Phase I ATTRACT Study Of ATG-201 In B Cell-Related Autoimmune Diseases	CI
08-25	Antengene's Autoimmune Disease Drug Candidate Approved for Phase I Trial in Australia	MT
08-21	Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-19	Antengene Presents Key R&D Highlights Including Atg-022 Clinical Data, Antengager and Trigager Tce Platforms, and Atg-207 Bifunctional Fusion Protein	CI
07-31	Antengene's CFO Steps Down; Chief Business Officer Named	MT
07-31	Antengene Corporation Limited Announces Management Changes, Effective August 1, 2026	CI
07-31	Antengene Corporation Limited Announces Resignation of Donald Andrew Lung as Chief Financial Officer, Effective August 1, 2026	CI
07-28	Antengene Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026	CI
07-13	Antengene Receives $60 Million Milestone in UCB Licensing Deal	MT
07-10	Soochow Securities Starts Antengene at Buy With HK$10.60 Price Target	MT

Antengene Corporation Limited Stock

Stocks

6996

KYG039571008

Biotechnology & Medical Research

Valuation: Antengene Corporation Limited

Chart: Antengene Corporation Limited

Latest news: Antengene Corporation Limited

Analysts' recommendations: Antengene Corporation Limited

Press Releases: Antengene Corporation Limited

Quotes and Performance

Price Extremes

Managers and Directors: Antengene Corporation Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

10-26	Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026	PR
10-09	Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026	PR
10-03	Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026	PR
09-21	Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022	PR
09-14	Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy	PR

1 day	-5.65%
1 week	-3.78%
Current month	-4.30%
1 month	-21.24%
3 months	-31.19%
6 months	-45.62%
Current year	-29.55%

1 week	2.62	2.99
1 month	2.62	3.54
Current year	2.62	6.28
1 year	2.62	6.28
3 years	0.5	8.16
5 years	0.5	13.06
10 years	0.5	22.5

Manager	Title	Age	Since
Jian Ming Mei CEO	Chief Executive Officer	60	28/08/2018
Bing Hou CTO	Chief Tech/Sci/R&D Officer	42	20/05/2026
Godfrey Guo CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jian Ming Mei CHM	Chairman	60	28/08/2018
Jing Qian BRD	Director/Board Member	51	09/11/2020
Rafael Fonseca BRD	Director/Board Member	59	14/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/09/26	Jing Qian	Other	Director	200,000	0.0294%
10/09/26	Bing Hou	Other		2,000,000	0.2944%
10/09/26	Rafael Fonseca	Other	Director	200,000	0.0294%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANTENGENE CORPORATION LIMITED	-5.65%	-3.78%	-47.85%	+72.26%	248M
WUXI APPTEC CO., LTD.	-2.37%	-5.03%	+39.49%	+62.39%	62.23B
ARGENX SE	+0.03%	+0.18%	+10.48%	+68.43%	54.92B
LONZA GROUP AG	-0.11%	+1.79%	+20.03%	+96.66%	55.26B
IQVIA HOLDINGS INC.	-3.33%	-5.54%	+19.39%	+35.69%	42.59B
BEONE MEDICINES AG	-2.45%	-2.59%	+16.36%	+98.45%	41.08B
REVOLUTION MEDICINES, INC.	-1.64%	+2.32%	+219.80%	+789.69%	40.33B
GENMAB A/S	+0.76%	+24.36%	+99.89%	+84.50%	33.12B
CELLTRION, INC.	+0.21%	+1.05%	+14.81%	+46.96%	32.61B
INSMED INCORPORATED	-2.90%	+17.12%	-42.35%	+337.07%	23.98B
Average	-1.74%	+3.47%	+35.01%	+169.21%	38.64B
Weighted average by Cap.	-1.29%	+2.74%	+44.69%	+162.61%

	2026 *	2027 *
Net sales	830M 980M 125M 111M 102M 93.04M 174M 11.82B 178M 1.22B 492M 6.24B 469M 459M 19.7B	338M 398M 50.78M 45.34M 41.6M 37.84M 70.95M 4.81B 72.36M 497M 200M 2.54B 191M 187M 8.01B
Net income	333M 393M 50.11M 44.74M 41.05M 37.34M 70.01M 4.74B 71.41M 490M 198M 2.5B 188M 184M 7.91B	-84.79M -100M -12.75M -11.38M -10.44M -9.5M -17.81M -1.21B -18.17M -125M -50.29M -637M -47.85M -46.83M -2.01B
Net Debt	-	-